{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:44:20Z","timestamp":1792226660183,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.semdp.2025.150942","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T06:47:44Z","timestamp":1753426064000},"page":"150942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Flow cytometry in the diagnosis and prognosis of multiple myeloma"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2832-2039","authenticated-orcid":false,"given":"Adam C.","family":"Seegmiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semdp.2025.150942_bib0001","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","article-title":"Plasma cell neoplasms and related entities \u2013 evolution in diagnosis and classification","volume":"482","author":"Fend","year":"2023","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.semdp.2025.150942_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cyto.b.21228","article-title":"Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting","volume":"90","author":"Arroz","year":"2016","journal-title":"Cytom B Clin Cytom"},{"issue":"9","key":"10.1016\/j.semdp.2025.150942_bib0003","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.V76.9.1739.1739","article-title":"Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry","volume":"76","author":"Terstappen","year":"1990","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semdp.2025.150942_bib0004","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.3324\/haematol.2017.169235","article-title":"Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection","volume":"102","author":"Oberle","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.semdp.2025.150942_bib0005","first-page":"e190","article-title":"Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma","volume":"32","author":"Reid","year":"2010","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.semdp.2025.150942_bib0006","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3892\/ijo.2012.1545","article-title":"Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide","volume":"41","author":"Kawano","year":"2012","journal-title":"Int J Oncol"},{"issue":"S1","key":"10.1016\/j.semdp.2025.150942_bib0007","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/ijlh.13562","article-title":"Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: current paradigm, guidelines, and future applications","volume":"43","author":"Soh","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"7","key":"10.1016\/j.semdp.2025.150942_bib0008","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.semdp.2025.150942_bib0009","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.semdp.2025.150942_bib0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/ajcp\/aqad086","article-title":"Camelid-derived CD38 antibody successfully circumvents epitope blockade by the therapeutic anti-CD38 antibody daratumumab","volume":"160","author":"ElMaraashly","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.semdp.2025.150942_bib0011","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3324\/haematol.2010.036814","article-title":"Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma","volume":"96","author":"Atanackovic","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.semdp.2025.150942_bib0012","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cyto.b.21269","article-title":"Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases","volume":"90","author":"Pojero","year":"2016","journal-title":"Cytom B Clin Cytom"},{"issue":"2","key":"10.1016\/j.semdp.2025.150942_bib0013","first-page":"221","article-title":"VS38 identifies myeloma cells with dim CD38 expression and plasma cells following daratumumab therapy, which interferes with detection for 4 to 6 months","volume":"153","author":"Courville","year":"2020","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.semdp.2025.150942_bib0014","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/cyto.b.21961","article-title":"CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab","volume":"100","author":"Soh","year":"2021","journal-title":"Cytom. B Clin Cytom"},{"issue":"5","key":"10.1016\/j.semdp.2025.150942_bib0015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2141.2006.06068.x","article-title":"Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration","volume":"133","author":"Nadav","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.semdp.2025.150942_bib0016","doi-asserted-by":"crossref","first-page":"951","DOI":"10.5858\/2007-131-951-QOPCIB","article-title":"Quantiation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment","volume":"131","author":"Smock","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"S1","key":"10.1016\/j.semdp.2025.150942_bib0017","first-page":"S47","article-title":"Human peripheral blood B-cell compartments: a crossroad in B-cell traffic","volume":"78","author":"Perez-Andres","year":"2010","journal-title":"Cytom. B Clin Cytom"},{"issue":"1","key":"10.1016\/j.semdp.2025.150942_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF00320578","article-title":"Bone-marrow plasmocytosis\u2014An immunohistochemical study","volume":"53","author":"Eckert","year":"1986","journal-title":"Blut"},{"issue":"4","key":"10.1016\/j.semdp.2025.150942_bib0019","first-page":"958","article-title":"Plasma cell subtypes in bone marrow biopsies from patients without plasma cell dyscrasia","volume":"114","author":"Markey","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.semdp.2025.150942_bib0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cyto.b.22068","article-title":"Relevance of polyclonal plasma cells and post-therapy immunomodulation in measurable residual disease assessment in multiple myeloma","volume":"102","author":"Das","year":"2022","journal-title":"Cytom B Clin Cytom"},{"issue":"4","key":"10.1016\/j.semdp.2025.150942_bib0021","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cyto.b.20517","article-title":"Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology","volume":"78","author":"Cannizzo","year":"2010","journal-title":"Cytom B Clin Cytom"},{"issue":"3","key":"10.1016\/j.semdp.2025.150942_bib0022","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.leukres.2013.12.007","article-title":"Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases","volume":"38","author":"Tembhare","year":"2014","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.semdp.2025.150942_bib0023","first-page":"137","article-title":"Immunphenotype of normal and myelomatous plasma-cell subsets","volume":"31","author":"Robillard","year":"2014","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.semdp.2025.150942_bib0024","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1179\/1024533212Z.000000000146","article-title":"Immunohistochemical analysis in diagnosis of plasma cell myeloma based on cytoplasmic kappa\/lambda ratio of CD38-positive plasma cells","volume":"17","author":"Nakayama","year":"2012","journal-title":"Hematology"},{"issue":"5","key":"10.1016\/j.semdp.2025.150942_bib0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/cyto.b.21893","article-title":"Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma","volume":"98","author":"Bayly","year":"2020","journal-title":"Cytom B Clin Cytom"},{"issue":"4","key":"10.1016\/j.semdp.2025.150942_bib0026","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.semdp.2025.150942_bib0027","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1309\/5EL22BH45PHUPM8P","article-title":"Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma","volume":"127","author":"Seegmiller","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.semdp.2025.150942_bib0028","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunphenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytom B Clin Cytom"},{"issue":"12","key":"10.1016\/j.semdp.2025.150942_bib0029","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/sj.leu.2401211","article-title":"The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma","volume":"12","author":"Pellat-Deceunynck","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.semdp.2025.150942_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.leukres.2016.03.003","article-title":"The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma","volume":"44","author":"Gonsalves","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.semdp.2025.150942_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108363","article-title":"CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma","volume":"213","author":"Chu","year":"2020","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.semdp.2025.150942_bib0032","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1002\/cam4.1840","article-title":"Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis","volume":"7","author":"Chen","year":"2018","journal-title":"Cancer Med"},{"issue":"16","key":"10.1016\/j.semdp.2025.150942_bib0033","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","article-title":"Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semdp.2025.150942_bib0034","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2002-11-3333","article-title":"CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma","volume":"102","author":"Robillard","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semdp.2025.150942_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/893243","article-title":"Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma","volume":"2014","author":"Shim","year":"2014","journal-title":"Biomed Res Int"},{"issue":"9","key":"10.1016\/j.semdp.2025.150942_bib0036","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1080\/10428194.2019.1574003","article-title":"Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib","volume":"60","author":"Oka","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.semdp.2025.150942_bib0037","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood-2002-12-3784","article-title":"Expression of CD52 on plasma cells in plasma cell proliferative disorders","volume":"102","author":"Kumar","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semdp.2025.150942_bib0038","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cyto.b.21351","article-title":"Potential therapeutic targets in plasma cell disorders: a flow cytometry study","volume":"92","author":"Lisenko","year":"2017","journal-title":"Cytom B Clin Cytom"},{"issue":"11","key":"10.1016\/j.semdp.2025.150942_bib0039","first-page":"1577","article-title":"CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy","volume":"91","author":"Rawstron","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.semdp.2025.150942_bib0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1309\/AJCP59UORCYZEVQO","article-title":"Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma","volume":"137","author":"Alapat","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"10.1016\/j.semdp.2025.150942_bib0041","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/jclinpath-2014-202421","article-title":"Diagnostic and prognostic significance of CD200 expression and its stability in plasma cell myeloma","volume":"67","author":"Douds","year":"2014","journal-title":"J Clin Pathol"},{"issue":"13","key":"10.1016\/j.semdp.2025.150942_bib0042","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma","volume":"108","author":"Moreaux","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semdp.2025.150942_bib0043","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.beha.2017.07.002","article-title":"How do we measure MRD in ALL and how should measurements affect decisions re: treatment and prognosis?","volume":"30","author":"Chen","year":"2017","journal-title":"Best Pr Res Clin Haematol"},{"issue":"10","key":"10.1016\/j.semdp.2025.150942_bib0044","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semdp.2025.150942_bib0045","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.semdp.2025.150942_bib0046","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.semdp.2025.150942_bib0047","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"Roussel","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.semdp.2025.150942_bib0048","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.semdp.2025.150942_bib0049","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Stetler-Stevenson","year":"2016","journal-title":"Cytom B Clin Cytom"},{"issue":"12","key":"10.1016\/j.semdp.2025.150942_bib0050","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.semdp.2025.150942_bib0051","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12185-019-02615-z","article-title":"Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry","volume":"109","author":"Takamatsu","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.semdp.2025.150942_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.708231","article-title":"Ten color multiparameter flow cytometry in bone marrow and apheresis products for assessment and outcome prediction in multiple myeloma patients","volume":"11","author":"Riebl","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.semdp.2025.150942_bib0053","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/leu.2014.321","article-title":"Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential","volume":"29","author":"Paino","year":"2015","journal-title":"Leukemia"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257025000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257025000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T06:54:16Z","timestamp":1753944856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257025000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0740257025000784"],"URL":"https:\/\/doi.org\/10.1016\/j.semdp.2025.150942","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flow cytometry in the diagnosis and prognosis of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semdp.2025.150942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"150942"}}